On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 49:43 NS Pharma’s Exon 53 Skipping Program Update (April 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:01:32 Gene Therapy: A Closer Look (March 2018) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 1:02:50 Pulmonary Care in Adults with Duchenne (March 2018) 7 years ago Care Webinars,Webinars 50:27 Positive Data from Summit’s PhaseOUT DMD Ezutromid Clinical Trial (February 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 53:55 Italfarmaco Provides Givinostat Update (January 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:05:47 Understanding Gene Therapy, Part 3 – Galgt2 and Dup2 (December 2017) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 50:36 Capricor Therapeutics’ HOPE-Duchenne Clinical Trial (November 2017) 7 years ago Research & Clinical Trial Webinars,Webinars 1:05:15 Wave Life Sciences (November 2017) 7 years ago Research & Clinical Trial Webinars,Webinars «1…1516171819…25»Page 17 of 25
by: Parent Project Muscular Dystrophy
